Innate immune signaling in cardiac ischemia
- PMID: 21448140
- DOI: 10.1038/nrcardio.2011.38
Innate immune signaling in cardiac ischemia
Abstract
Despite advances in treatment of patients who suffer from ischemic heart disease, morbidity related to myocardial infarction is increasing in Western societies. Acute and chronic immune responses elicited by myocardial ischemia have an important role in the functional deterioration of the heart. Research on modulation of the inflammatory responses was focused on effector mediators such as leukocytes. However, increasing evidence indicates that various endogenous ligands that act as 'danger signals', also called danger-associated molecular patterns (DAMPs), are released upon injury and modulate inflammation. Originally described as part of the first-line defense against invading microorganisms, several Toll-like receptors (TLRs) on leukocytes and parenchymal cells have now been shown to respond to such signals and to have a pivotal role in noninfectious pathological cardiovascular conditions, such as ischemia-reperfusion injury and heart failure. From a therapeutic perspective, DAMPs are attractive targets owing to their specific induction after injury. In this Review, we will discuss innate immune activation through TLRs in cardiac ischemia mediated by DAMPs.
Similar articles
-
Toll-like receptors: new players in myocardial ischemia/reperfusion injury.Antioxid Redox Signal. 2011 Oct 1;15(7):1875-93. doi: 10.1089/ars.2010.3723. Epub 2011 Apr 8. Antioxid Redox Signal. 2011. PMID: 21091074 Free PMC article. Review.
-
Insights into innate immune signalling in controlling cardiac remodelling.Cardiovasc Res. 2017 Nov 1;113(13):1538-1550. doi: 10.1093/cvr/cvx130. Cardiovasc Res. 2017. PMID: 29088374 Review.
-
Paying for the Tolls: The High Cost of the Innate Immune System for the Cardiac Myocyte.Adv Exp Med Biol. 2017;1003:17-34. doi: 10.1007/978-3-319-57613-8_2. Adv Exp Med Biol. 2017. PMID: 28667552 Review.
-
The innate immune response in reperfused myocardium.Cardiovasc Res. 2012 May 1;94(2):276-83. doi: 10.1093/cvr/cvs018. Epub 2012 Jan 20. Cardiovasc Res. 2012. PMID: 22266751 Review.
-
Innate immunity and cardiomyocytes in ischemic heart disease.Life Sci. 2014 Mar 28;100(1):1-8. doi: 10.1016/j.lfs.2014.01.062. Epub 2014 Jan 28. Life Sci. 2014. PMID: 24486305 Free PMC article. Review.
Cited by
-
Anti-inflammatory mechanisms and therapeutic opportunities in myocardial infarct healing.J Mol Med (Berl). 2012 Apr;90(4):361-9. doi: 10.1007/s00109-011-0847-y. Epub 2012 Jan 7. J Mol Med (Berl). 2012. PMID: 22228177 Review.
-
Biosynthesis of oxidized lipid mediators via lipoprotein-associated phospholipase A2 hydrolysis of extracellular cardiolipin induces endothelial toxicity.Am J Physiol Lung Cell Mol Physiol. 2016 Aug 1;311(2):L303-16. doi: 10.1152/ajplung.00038.2016. Epub 2016 May 27. Am J Physiol Lung Cell Mol Physiol. 2016. PMID: 27233995 Free PMC article.
-
Spike-based adenovirus vectored COVID-19 vaccine does not aggravate heart damage after ischemic injury in mice.Commun Biol. 2022 Sep 2;5(1):902. doi: 10.1038/s42003-022-03875-y. Commun Biol. 2022. PMID: 36056135 Free PMC article.
-
N-terminal truncated intracellular matrix metalloproteinase-2 induces cardiomyocyte hypertrophy, inflammation and systolic heart failure.PLoS One. 2013 Jul 16;8(7):e68154. doi: 10.1371/journal.pone.0068154. Print 2013. PLoS One. 2013. PMID: 23874529 Free PMC article.
-
Interleukin-1 in cardiac injury, repair, and remodeling: pathophysiologic and translational concepts.Discoveries (Craiova). 2015 Jan-Mar;3(1):e41. doi: 10.15190/d.2015.33. Discoveries (Craiova). 2015. PMID: 26273700 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources